View Future GrowthGenomma Lab Internacional. de 過去の業績過去 基準チェック /26Genomma Lab Internacional. deは、平均年間6.8%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.7% 4.4%収益成長率で 成長しています。 Genomma Lab Internacional. deの自己資本利益率は13.7%であり、純利益率は9.3%です。主要情報6.80%収益成長率7.48%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率4.36%株主資本利益率13.69%ネット・マージン9.25%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Apr 01Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025お知らせ • Feb 11Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024すべての更新を表示Recent updatesお知らせ • Apr 14+ 1 more updateGenomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexicoお知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026お知らせ • Dec 09Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding.お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Jun 24Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.お知らせ • Apr 08Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexicoお知らせ • Apr 01Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025お知らせ • Mar 07Genomma Lab Internacional Announces Eleventh Cash Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on March 14, 2025. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024 ("AGSM"), have therefore deemed it appropriate to make this announced dividend payment. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.お知らせ • Feb 11Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024お知らせ • Oct 03Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal CommitteeGenomma Lab Internacional, S.A.B. de C.V. announced that it has received Good Manufacturing Practices ("GMP") certification from the Mexican Ministry of Health's Federal Committee for Protection from Sanitary Risks for its oral liquid, topical liquid and tablet coating manufacturing production at Genomma Lab's Medicinas y Medicamentos Nacionales, S.A. de C.V. manufacturing facility in the State of Mexico.お知らせ • Jul 04Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024お知らせ • Jun 16Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024, have therefore deemed it appropriate to make this announced dividend payment.お知らせ • Apr 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024お知らせ • Mar 14Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00 payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 28, 2023 (AGSM), have therefore deemed it appropriate to make this seventh announced dividend payment.お知らせ • Jan 24Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2023 results After-Market on Feb 21, 2024お知らせ • Dec 14Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. (Genomma Lab) informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00, payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023.お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2023 results After-Market on Oct 25, 2023お知らせ • Jul 06Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023お知らせ • Jan 31Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2022 results After-Market on Feb 22, 2023収支内訳Genomma Lab Internacional. de の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:GNML.F 収益、費用、利益 ( )MXN Millions日付収益収益G+A経費研究開発費31 Mar 2617,3251,6037,274031 Dec 2517,5411,6077,292030 Sep 2518,1901,6557,714030 Jun 2518,8411,8817,944031 Mar 2518,8162,1587,979031 Dec 2418,6072,0918,055030 Sep 2417,4661,6637,432030 Jun 2416,7671,3737,121031 Mar 2416,4861,1596,965031 Dec 2316,4671,0856,889030 Sep 2317,0741,3926,988030 Jun 2317,0301,4217,002031 Mar 2316,9831,4086,932031 Dec 2216,8201,3666,922030 Sep 2216,7781,3597,185030 Jun 2216,4121,3537,043031 Mar 2215,9541,3286,877031 Dec 2115,4871,3086,570030 Sep 2114,8681,3526,135030 Jun 2114,3121,3685,872031 Mar 2114,0831,4165,736031 Dec 2013,8701,4045,666030 Sep 2013,6191,1795,899030 Jun 2013,2681,0035,824031 Mar 2012,9108865,810031 Dec 1912,7137505,824030 Sep 1912,6179355,815030 Jun 1912,2749255,735031 Mar 1911,9219865,615031 Dec 1811,7941,1095,578030 Sep 1811,5561,2425,264030 Jun 1811,9001,2495,378031 Mar 1811,8861,2185,454031 Dec 1712,0781,2795,622030 Sep 1711,8989586,295030 Jun 1711,7411,2126,383031 Mar 1711,669-1,6037,551031 Dec 1611,316-1,6817,491030 Sep 1611,287-3,4478,438030 Jun 1610,988-3,7598,363031 Mar 1611,125-8957,325031 Dec 1511,042-1,1377,334030 Sep 1511,2111,1095,791030 Jun 1511,9461,4105,8680質の高い収益: GNML.Fは 高品質の収益 を持っています。利益率の向上: GNML.Fの現在の純利益率 (9.3%)は、昨年(11.5%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: GNML.Fの収益は過去 5 年間で年間6.8%増加しました。成長の加速: GNML.Fは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: GNML.Fは過去 1 年間で収益成長率がマイナス ( -25.7% ) となったため、 Pharmaceuticals業界平均 ( -5% ) と比較することが困難です。株主資本利益率高いROE: GNML.Fの 自己資本利益率 ( 13.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 07:05終値2026/04/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genomma Lab Internacional, S.A.B. de C.V. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Antonio Hernandez Velez LeijaActinver Case de Bolsa, S.A. de C.V.Benjamin TheurerBarclaysRobert Ford AguilarBofA Global Research10 その他のアナリストを表示
お知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026
お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Apr 01Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025
お知らせ • Feb 11Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025
お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
お知らせ • Apr 14+ 1 more updateGenomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 29, 2026. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexico
お知らせ • Jan 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 25, 2026Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2025 results After-Market on Feb 25, 2026
お知らせ • Dec 09Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company presented a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on December 23, 2025. This amount per share is based on the total LABB shares currently outstanding.
お知らせ • Oct 09Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 22, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Jun 30Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 23, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Jun 24Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on July 1st, 2025. This amount per share is based on the total LABB shares currently outstanding. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.
お知らせ • Apr 08Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025Genomma Lab Internacional, S.A.B. de C.V., Annual General Meeting, Apr 24, 2025. Location: antonio dovali jaime no 70, tower c 2nd floor, santa fe neighborhood, cp 01210, mexico Mexico
お知らせ • Apr 01Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 30, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025
お知らせ • Mar 07Genomma Lab Internacional Announces Eleventh Cash Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N. (two hundred million pesos 00/100 National Currency), payable to shareholders of record of the applicable circulating shares at the close of business on March 14, 2025. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024 ("AGSM"), have therefore deemed it appropriate to make this announced dividend payment. Subject to the terms and conditions established by the AGSM, the Company has the intention to make dividend payments on a Quarterly basis.
お知らせ • Feb 11Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 26, 2025Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2024 results at 3:00 PM, Central Standard Time on Feb 26, 2025
お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
お知らせ • Oct 03Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal CommitteeGenomma Lab Internacional, S.A.B. de C.V. announced that it has received Good Manufacturing Practices ("GMP") certification from the Mexican Ministry of Health's Federal Committee for Protection from Sanitary Risks for its oral liquid, topical liquid and tablet coating manufacturing production at Genomma Lab's Medicinas y Medicamentos Nacionales, S.A. de C.V. manufacturing facility in the State of Mexico.
お知らせ • Jul 04Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024
お知らせ • Jun 16Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 30, 2024, have therefore deemed it appropriate to make this announced dividend payment.
お知らせ • Apr 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024
お知らせ • Mar 14Genomma Lab Internacional, S.A.B. De C.V. Declares Cash DividendGenomma Lab Internacional, S.A.B. de C.V. informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00 payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024. This amount per share is based on the total LABB shares currently outstanding. Genomma's Board of Directors, exercising the powers delegated at the Annual General Shareholders Meeting held on April 28, 2023 (AGSM), have therefore deemed it appropriate to make this seventh announced dividend payment.
お知らせ • Jan 24Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2023 results After-Market on Feb 21, 2024
お知らせ • Dec 14Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend PaymentGenomma Lab Internacional, S.A.B. de C.V. (Genomma Lab) informed that the Company filed a Notice of Rights with the Mexican Stock Exchange (Bolsa Mexicana de Valores) declaring a cash dividend of MXN 0.196080 per share on its common stock representing a total amount of MXN 200,001,600.00, payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023.
お知らせ • Oct 05Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q3, 2023 results After-Market on Oct 25, 2023
お知らせ • Jul 06Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023
お知らせ • Jan 31Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023Genomma Lab Internacional, S.A.B. de C.V. announced that they will report Q4, 2022 results After-Market on Feb 22, 2023